newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discoveryClinical updates expected by end of year for the Phase 1 dose-escalation IMMUNICY-1